Regeneron sees vacated Dell plant key to future production needs

Sales of Regeneron's ($REGN) sight-saving drug Eylea have been beating expectations, and the drug is headed for blockbuster territory in its first full year since approval. But the Tarrytown, NY, company is looking ahead, buying a former Dell computer plant in Ireland which it will retrofit for its own needs. Regeneron Vice President Peter Dworkin said the company will start work on the 400,000-square-foot facility in Limerick as soon as local permits are obtained. The company isn't saying what it is paying for the plant, but in a financial filing it said it expects to spend $250 million to $300 million on capital projects through next year, including buying and starting work on the plant in Limerick. Dworkin points out, however, that that figure includes expansion and new offices at its manufacturing center in Rensselaer, NY, as well as new offices and laboratories at its Tarrytown headquarters. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.